Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers

E.F.P.M. Vuurman*, E.L. Theunissen, A.C.M. van Oers, C.J. van Leeuwen, J. Jolles

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

361 Downloads (Pure)


Introduction Rupatadine fumarate is a potent, selective, histamine HI-receptor antagonist and PAF inhibitor with demonstrated efficacy for the relief of allergic rhinitis. Rupatadine does not easily cross the blood-brain barrier and is believed to be non-sedating at therapeutic doses. Consequently, rupatadine should show no impairment on car driving. Objective This study compared the acute effects of rupatadine, relative to placebo and hydroxyzine (as an active control), on healthy subjects' driving performance. Methods Twenty subjects received a single dose of rupatadine 10 mg, hydroxyzine 50 mg, or placebo in each period of this randomized, double-blind, three-way crossover study. Two hours postdosing, subjects operated a specially instrumented vehicle in tests designed to measure their driving ability. Before and after the driving tests ratings of sedation were recorded. Results There was no significant difference between rupatadine and placebo in the primary outcome variable: standard deviation of lateral position (SDLP); however, hydroxyzine treatment significantly increased SDLP (p <0.001 for both comparisons). Objective (Stanford sleepiness scale) and subjective sedation ratings (Visual Analogue Scales) showed similar results: subjects reported negative effects after hydroxyzine but not after rupatadine. Conclusion Rupatadine 10 mg is not sedating and does not impair driving performance.
Original languageEnglish
Pages (from-to)289-297
JournalHuman Psychopharmacology-Clinical and Experimental
Issue number5
Publication statusPublished - 1 Jan 2007

Cite this